Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Bauer

Showing results (341-350 of 408) with videos related to

Pageof 41
Sort By:
Epilepsia|June 27, 2018
Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticusAdam Strzelczyk, Lara Kay, Sebastian Bauer, et al.
Cancer|January 10, 2018
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)Michael Montemurro, Angela Cioffi, Julien Dômont, et al.
British Journal of Cancer|May 25, 2019
Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursCésar Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
Cancer|April 17, 2014
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinibHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 24, 2025
<sup>90</sup>Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous TumorsHelena Lanzafame, Christoph E Heilig, Eva Wardelmann, et al.
British Journal of Cancer|February 23, 2019
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursCésar Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
The Oncologist|January 16, 2021
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of TherapySuzanne George, Robin L Jones, Sebastian Bauer, et al.
Molecular Cancer Therapeutics|July 17, 2019
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage StrategyThomas Mühlenberg, Julia Ketzer, Michael C Heinrich, et al.
The Oncologist|July 27, 2021
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS StudyJohn R Zalcberg, Michael C Heinrich, Suzanne George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III TrialSebastian Bauer, Robin L Jones, Jean-Yves Blay, et al.
Pageof 41

Showing results (341-350 of 408) with videos related to

Sort By:
Pageof 41
Epilepsia|June 27, 2018
Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticusAdam Strzelczyk, Lara Kay, Sebastian Bauer, et al.
Cancer|January 10, 2018
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)Michael Montemurro, Angela Cioffi, Julien Dômont, et al.
British Journal of Cancer|May 25, 2019
Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursCésar Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
Cancer|April 17, 2014
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinibHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 24, 2025
<sup>90</sup>Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous TumorsHelena Lanzafame, Christoph E Heilig, Eva Wardelmann, et al.
British Journal of Cancer|February 23, 2019
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursCésar Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
The Oncologist|January 16, 2021
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of TherapySuzanne George, Robin L Jones, Sebastian Bauer, et al.
Molecular Cancer Therapeutics|July 17, 2019
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage StrategyThomas Mühlenberg, Julia Ketzer, Michael C Heinrich, et al.
The Oncologist|July 27, 2021
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS StudyJohn R Zalcberg, Michael C Heinrich, Suzanne George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III TrialSebastian Bauer, Robin L Jones, Jean-Yves Blay, et al.
Pageof 41